908 Devices Inc. (NASDAQ:MASS) Expected to Earn Q1 2025 Earnings of ($0.31) Per Share

908 Devices Inc. (NASDAQ:MASS) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of 908 Devices in a note issued to investors on Tuesday, April 30th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings of ($0.31) per share for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.16) EPS.

908 Devices Price Performance

908 Devices stock opened at $5.65 on Thursday. The company has a market cap of $186.34 million, a price-to-earnings ratio of -5.28 and a beta of 1.02. 908 Devices has a 12 month low of $4.85 and a 12 month high of $12.51. The stock’s 50-day moving average is $6.54 and its 200-day moving average is $7.06.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.03. 908 Devices had a negative net margin of 68.57% and a negative return on equity of 20.47%. The company had revenue of $9.99 million for the quarter, compared to analyst estimates of $9.29 million. During the same quarter last year, the business earned ($0.39) EPS. 908 Devices’s revenue for the quarter was up 5.3% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AWM Investment Company Inc. acquired a new position in shares of 908 Devices during the 3rd quarter valued at $3,740,000. ARK Investment Management LLC grew its stake in shares of 908 Devices by 8.3% in the fourth quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company’s stock valued at $48,769,000 after buying an additional 333,119 shares in the last quarter. Iron Triangle Partners LP raised its holdings in shares of 908 Devices by 31.1% during the 4th quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company’s stock valued at $14,417,000 after buying an additional 304,484 shares during the period. Granahan Investment Management LLC boosted its holdings in 908 Devices by 10.6% in the 4th quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company’s stock worth $22,874,000 after acquiring an additional 195,368 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in 908 Devices by 3.0% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company’s stock valued at $4,196,000 after purchasing an additional 18,492 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.